江化微(603078.SH):四川江化微擬向銀行貸款合計1.8億元
格隆匯6月19日丨江化微(603078.SH)公佈,四川江化微電子材料有限公司(以下簡稱“四川江化微”)為公司全資子公司,註冊資金1億元人民幣,產品主要服務於川渝地區客户使用。現由於四川江化微“年產6萬噸超高純濕電子化學品項目”、“年產3萬噸超高純濕電子化學品、副產0.2萬噸工業級化學品再生利用項目”建設需要,四川江化微與中國建設銀行股份有限公司彭山支行於2020年6月19日簽署兩份貸款合同,該貸款合同借款金額分別為人民幣1.22億元整和人民幣5800萬元整,借款期限為72月,即從2020年6月19日起至2026年6月18日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.